# US 9,855,297 B2 · Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,855,297 B2
- Document ID: US9855297B2
- Status: Granted
- Kind: B2
- Application number: 15/045,368
- Filed: 2016-02-17
- Published: 2016-06-30
- Granted: 2018-01-02
- Earliest claimed: 2013-05-29
- Assignees: Cellectis
- Applicants: Cellectis
- Inventors: Philippe Duchateau; André Choulika; Laurent Poirot
- Web page: https://patentgrep.com/patent/US9855297B2

## CPC

- C12N 15/85: for animal cells
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/4211: {CD19 or B4}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C12N 5/0636: {T lymphocytes}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12Y 301/00: Hydrolases acting on ester bonds (3.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

## Claims

### Claim 1

A method of preparing genetically modified primary T-cells for immunotherapy comprising the steps of:
(a) transfecting mRNA encoding an RNA-guided endonuclease into the primary T-cells, wherein the RNA-guided endonuclease is expressed from the transfected m RNA;
(b) introducing a DNA vector that encodes a specific guide RNA, wherein the specific guide RNA directs the RNA-guided endonuclease to at least one targeted locus in the T-cell genome into the primary T-cells;
(c) cleaving the at least one targeted locus in the T-cell genome with the RNA-guided endonuclease;
(d) generating a genetic modification at the site of the cleavage; and
(e) expanding the resulting genetically modified T-cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the RNA-guided endonuclease is Cas9.

### Claim 3 (depends on 1)

The method of claim 1, wherein the transfected mRNA is stabilized by including modified nucleic acid bases or polyadenylation sequences, by adjunction of ARCA (Anti-Reverse Cap Analog), or by adjunction of 5′ or 3′ UTR.

### Claim 4 (depends on 1)

The method of claim 1, wherein the transfected mRNA is coupled with at least one cell-penetrating peptide selected from penetratin, TAT, polyarginine peptide, pVEC, MPG, Transportan, Guanidium rich molecular transporter.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mRNA encoding an RNA-guided endonuclease is transfected into the cells by electroporation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the guide RNA is introduced into the T-cells by pseudo-transduction.

### Claim 7 (depends on 1)

The method of claim 1, wherein at least one targeted locus encodes a component of the T-cell receptor (TCR).

### Claim 8 (depends on 7)

The method of claim 7, wherein the component of the T-cell receptor is TCRα.

### Claim 9 (depends on 8)

The method of claim 8, wherein the guide RNA specifically hybridizes to a target sequence of TCRα selected from SEQ ID NO:6 to SEQ ID NO:52.

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one targeted locus is the PD1 or CTLA-4 gene.

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one targeted locus comprises two targeted loci selected from the group consisting of PD1 and TCR alpha, PD1 and TCR beta, CTLA-4 and TCR alpha, CTLA-4 and TCR beta, LAG3 and TCR alpha, LAG3 and TCR beta, Tim3 and TCR alpha, Tim3 and TCR beta, BTLA and TCR alpha, BTLA and TCR beta, BY55 and TCR alpha, BY55 and TCR beta, TIGIT and TCR alpha, TIGIT and TCR beta, B7H5 and TCR alpha, B7H5 and TCR beta, LAIR1 and TCR alpha, LAIR1 and TCR beta, SIGLEC10 and TCR alpha, SIGLEC10 and TCR beta, 2B4 and TCR alpha, 2B4 and TCR beta genes.

### Claim 12 (depends on 1)

The method of claim 1, wherein the at least one targeted locus is selected from CD52, hypoxanthine-guanine phosphoribosyltransferase (HPRT), and glucocorticoid receptor (GR) genes.

### Claim 13 (depends on 1)

The method of claim 1, further comprising introducing into the genetically modified T-cells a chimeric antigen receptor (CAR).

### Claim 14 (depends on 13)

The method of claim 13, wherein the CAR is an anti-CD19 CAR.

### Claim 15 (depends on 1)

The method of claim 1, wherein the DNA vector comprises a U6 promoter.

### Claim 16 (depends on 1)

The method of claim 1, wherein the DNA vector is a viral vector that encodes the specific guide RNA.

### Claim 17 (depends on 1)

The method of claim 1, comprising transfecting a plasmid vector that encodes the specific guide RNA.
